At concentrations of H-1152 and the upstream MVA pathway inhibitor, Simvastatin, at which neither alone inhibited proliferation, the combination cooperated to selectively antagonize proliferation of tumor cells with endogenous p53 DNA contact mutations (Supplementary Fig. 7), supporting that the two inhibitors biochemically target different components within the same pathway. The gene discussed is TP53; the disease is neoplasm.